CARGO Therapeutics, Inc. Common Stock (CRGX) NASDAQ
4.47
+0(+0.00%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
4.47
+0(+0.00%)
Currency In USD
Address
1900 Alameda De Las Pulgas
San Mateo, DE 94403
United States of America (the)
Phone
650-379-6143
Website
Sector
Healthcare
Industry
Biotechnology
Employees
167
First IPO Date
November 13, 2023
| Name | Title | Pay | Year Born |
| Anup Radhakrishnan | Interim Chief Executive Officer, Chief Financial Officer, Secretary & Chief Operating Officer | 685,937 | 1980 |
| Crystal L. Mackall | Co-Founder & Scientific Advisory Board Chair | 160,000 | 1961 |
| Shishir Gadam | Chief Technical Officer | 674,033 | 1968 |
| Nancy Goodman | Founder | 0 | N/A |
| Louai Labanieh | Founder | 0 | N/A |
| Michael Ports | Chief Scientific Officer | 0 | 1982 |
| Robbie Majzner | Co-Founder & Scientific Advisory Board Member | 0 | N/A |
| Brett Masterson | Head of Marketing | 0 | N/A |
| Erik Poulsen | Head of Regulatory Affairs | 0 | N/A |
| Faisal Shawwa | Senior Vice President of Finance & Accounting | 0 | N/A |
| Kari E. Leetch | Chief People Officer | 0 | N/A |
| Halley E. Gilbert | Chief Legal Officer | 0 | 1970 |
CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is headquartered in San Mateo, California.